Main targets are the immune checkpoints cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1), receptors located on T-cells that regulate immune responses at the priming phase in lymph nodes and at the effector phase in the tumor, respectively [21]. The gene discussed is CTLA4; the disease is neoplasm.